# Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy

> **NCT07436182** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Mansoura University** · enrollment: 176 (estimated)

## Conditions studied

- Mitochondria
- Metformin

## Interventions

- **DRUG:** Imeglimin
- **DRUG:** Metformin 1000 mg Oral Tablet

## Key facts

- **NCT ID:** NCT07436182
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07436182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07436182, "Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07436182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*